.

Deeper Knowledge, Faster

  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Accenture
Queensland Health
Citi
Argus Health
Fish and Richardson
Cerilliant
Medtronic
US Army
QuintilesIMS
Colorcon

Generated: June 26, 2017

DrugPatentWatch Database Preview

Amphetamine - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for amphetamine and what is the scope of amphetamine patent protection?

Amphetamine
is the generic ingredient in twenty-three branded drugs marketed by Neos Theraps, Tris Pharma Inc, Teva, Actavis Elizabeth, Shire, Mylan Pharms Inc, Teva Womens, Barr, Aurolife Pharma Llc, Barr Labs Inc, Sandoz, Mallinckrodt Inc, Epic Pharma Llc, Impax Labs, Teva Pharms, Sun Pharm Inds, Ucb Inc, Lannett, and Arbor Pharms Llc, and is included in twenty-three NDAs. There are fourteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Amphetamine has twenty-one patent family members in fourteen countries.

There are fifty-three drug master file entries for amphetamine. Two suppliers are listed for this compound.

Summary for Generic Name: amphetamine

Tradenames:23
Patents:14
Applicants:19
NDAs:23
Drug Master File Entries: see list53
Suppliers / Packagers: see list2
Bulk Api Vendors: see list25
Clinical Trials: see list125
Patent Applications: see list20,282
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:amphetamine at DailyMed

Pharmacology for Ingredient: amphetamine

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ucb Inc
BIPHETAMINE 7.5
amphetamine resin complex; dextroamphetamine resin complex
CAPSULE, EXTENDED RELEASE;ORAL010093-009Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe
Teva
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE
amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate
CAPSULE, EXTENDED RELEASE;ORAL077488-004Apr 29, 2013ABRXNoNo► Subscribe► Subscribe
Teva Womens
ADDERALL 12.5
amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate
TABLET;ORAL011522-012Aug 31, 2000DISCNYesNo6,384,020*PED► SubscribeY► Subscribe
Actavis Elizabeth
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE
amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate
CAPSULE, EXTENDED RELEASE;ORAL077302-002Jun 22, 2012ABRXNoNo► Subscribe► Subscribe
Shire
ADDERALL XR 15
amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate
CAPSULE, EXTENDED RELEASE;ORAL021303-006May 22, 2002ABRXYesNoRE41148*PED► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: amphetamine

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,491,935Modified release formulations containing drug-ion exchange resin complexes► Subscribe
9,072,680Compositions comprising methylphenidate complexed with ion-exchange resin particles► Subscribe
8,790,700Modified release formulations containing drug-ion exchange resin complexes► Subscribe
9,198,864Modified release formulations containing drug-ion exchange resin complexes► Subscribe
9,549,989Modified release formulations containing drug-ion exchange resin complexes► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: amphetamine

Country Document Number Estimated Expiration
Russian Federation2008140944► Subscribe
South Korea101495146► Subscribe
Denmark2018160► Subscribe
Austria536867► Subscribe
Spain2396039► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

QuintilesIMS
Fuji
Johnson and Johnson
Express Scripts
Citi
Colorcon
Cerilliant
Novartis
Medtronic
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot